Table 4.

Adverse events

VariableRavulizumab (n = 97)Eculizumab (n = 98)
Patients with adverse events85 (87.6)86 (87.8)
Most common adverse events (≥5% of patients in either treatment group)
 Headache26 (26.8)17 (17.3)
 Nasopharyngitis21 (21.6)20 (20.4)
 Upper respiratory tract infection18 (18.6)10 (10.2)
 Diarrhea9 (9.3)7 (7.1)
 Pyrexia9 (9.3)5 (5.1)
 Nausea8 (8.2)9 (9.2)
 Constipation7 (7.2)5 (5.1)
 Influenza-like illness7 (7.2)8 (8.2)
 Abdominal pain6 (6.2)9 (9.2)
 Anemia6 (6.2)3 (3.1)
 Fatigue6 (6.2)6 (6.1)
 Vomiting6 (6.2)4 (4.1)
 Cough5 (5.2)10 (10.2)
 Pain in extremity5 (5.2)4 (4.1)
 Rhinitis5 (5.2)4 (4.1)
 Oropharyngeal pain4 (4.1)9 (9.2)
 Chest pain3 (3.1)9 (9.2)
 Dizziness3 (3.1)7 (7.1)
 Musculoskeletal pain2 (2.1)5 (5.1)
 Dyspnea0 (0.0)6 (6.1)
Patients with serious adverse events4 (4.1)8 (8.2)
Meningococcal infections00
Death00
Patients with adverse events leading to withdrawal of study drug00
Patients with serious adverse events leading to withdrawal of study drug00
  • Values are reported as n (%) of patients.